^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
New
Title:

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

Excerpt:
...we enrolled patients with confirmed anaplastic astrocytoma or glioblastoma...MGMT promoter methylation was associated with longer overall survival than was unmethylated status (11·9 months [95% CI 9·0 to not reached] vs 8·2 months [7·0-10·0]; HR 0·62, 95% CI 0·42-0·91, p=0·014). EFS was longer in patients with MGMT promoter methylation who received temozolomide...
DOI:
10.1016/S1470-2045(12)70164-X
Trial ID: